FDA-approved weight loss medications (semaglutide and tirzepatide) require either a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia
Potential side effects are typically minor, such as bruising at the injection site or mild vein irritation, which usually fade quickly
Certain warning signs, though, should be looked into: See a doctor within a few days: round, bald patches (suspected alopecia areata), redness, itching, burning or crusting on the scalp (suspected scarring alopecia, irreversible if untreated), or massive loss of more than 200 to 300 hairs a day over weeks
Soleno Therapeutics' DCCR (diazoxide choline controlled release) : DCCR is an orally administered, once-daily tablet that is designed to control hyperphagia and obesity in patients with Prader-Willi syndrome